MDA-MB-468from AcceGen |
|
ABC-TC0657 | 1 vial: Ask for price | |
Description: The MDA-MB-468 cell line was isolated in 1977 by R. Cailleau, et al., From a pleural effusion of a 51-year-old Black female patient with metastatic adenocarcinoma of the breast. |
|
MDA-MB-468 cellsfrom Addexbio |
|
C0006003 | One Frozen vial: 546.00 EUR | |
MDA-MB-468 Cell Linefrom Elabscience Biotech |
|
CL-0290 | 1×10⁶ cells/vial: 420.00 EUR | |
Description: Homo sapiens, Human |
|
GFP-Human MDA-MB-435(MDA-MB-435)from AcceGen |
|
ABC-RC211D | 1 vial: Ask for price | |
Description: Human MDA-MB-435 is a cell line isolated from the pleural effusion of a 31 year old female with metastatic, ductal adenocarcinoma of the breast. GFP-expressing MDA-MB-435 (GFP-MDA-MB-435) are selected from MDA-MB-435 cells after infected with lentiviruses expressing GFP with puromycin. The cells are shipped in a frozen vial with more than 5 x 105 cells/vial. Universal Full Growth Medium is recommended for cell culture and these cells have an average minimum population doubling levels > 20 when cultured following the detailed protocol described below. |
|
MDA-MB-436from Addexbio |
|
C0006032 | One Frozen vial: 546.00 EUR | |
MDA-MB-157from AcceGen |
|
ABC-TC0649 | 1 vial: Ask for price | |
Description: The cells express the WNT7B oncogene. Desmosomes, microvilli and tonofilaments were observed at boundaries between cells. |
|
MDA-MB-231from AcceGen |
|
ABC-TC0651 | 1 vial: Ask for price | |
Description: Species: human, Caucasian female 51 years old; Tissue: breast; Tumor: adenocarcinoma; Derived from: pleural effusion. |
|
MDA-MB-361from AcceGen |
|
ABC-TC0652 | 1 vial: Ask for price | |
Description: This line differs from others of the series in karyology and in that it was isolated from a brain metastasis. |
|
MDA-MB-415from AcceGen |
|
ABC-TC0653 | 1 vial: Ask for price | |
Description: The cells express the WNT7B oncogene. The patient presenting with the tumor was from Paraguay and, although listed as Caucasian, may have had mixed ancestry as suggested by the presence of G6PD type A phenotype in the cells. |
|
MDA-MB-436from AcceGen |
|
ABC-TC0655 | 1 vial: Ask for price | |
Description: The line is pleomorphic and most cells react intensely with anti tubulin antibody as demonstrated by indirect immunofluorescence staining. |
|
MDA-MB-453from AcceGen |
|
ABC-TC0656 | 1 vial: Ask for price | |
Description: MDA-MB-453 was derived in 1976 by R. Cailleau et al. From an effusion of a 48 year old female patient with metastatic carcinoma of the breast, involving the nodes, brain and both pleural and pericardial cavities.The cells overexpress FGF receptors. |
|
MDA-MB-361from Addexbio |
|
C0006051 | One Frozen vial: 500.00 EUR | |
MDA-MB-435Sfrom AcceGen |
|
ABC-TC0654 | 1 vial: Ask for price | |
Description: MDA-MB-435S is a spindle shaped strain which evolved from the parent line (435) isolated in 1976 (R. Cailleau et al.) From the pleural effusion of a 31 year old female with metastatic ductal adenocarcinoma of the breast. |
|
MDA-MB-134-VIfrom AcceGen |
|
ABC-TC0648 | 1 vial: Ask for price | |
Description: This is one of a series of breast tumor lines isolated from pleural effusions and characterized by R. Cailleau and associates in 1973. The cells grow a monolayer of round loosely adherent cells. |
|
MDA-MB-231 cellsfrom Addexbio |
|
C0006002 | One Frozen vial: 546.00 EUR | |
MDA-MB-157 cellsfrom Addexbio |
|
C0006020 | One Frozen vial: 546.00 EUR | |
MDA-MB-175-VIIfrom AcceGen |
|
ABC-TC0650 | 1 vial: Ask for price | |
Description: This is one of a series of breast tumor lines isolated from pleural effusions and characterized by R. Cailleau and associates in 1973. The cells grow a monolayer of round loosely adherent cells. |
|
MDA-MB-175VII cellsfrom Addexbio |
|
C0006009 | One Frozen vial: 582.00 EUR | |
MDA-MB-231 Cell Linefrom Elabscience Biotech |
|
CL-0150 | 1×10⁶ cells/vial: 420.00 EUR | |
Description: Homo sapiens, Human |
|
MDA-MB-453 Cell Linefrom Elabscience Biotech |
|
CL-0152 | 1×10⁶ cells/vial: 420.00 EUR | |
Description: Homo sapiens, Human |
|
MDA-MB-415 Cell Linefrom Elabscience Biotech |
|
CL-0382 | 1×10⁶ cells/vial: 500.00 EUR | |
Description: Homo sapiens, Human |
|
MDA-MB-436 Cell Linefrom Elabscience Biotech |
|
CL-0383 | 1×10⁶ cells/vial: 500.00 EUR | |
Description: Homo sapiens, Human |
|
MDA-MB-361 Cell Linefrom Elabscience Biotech |
|
CL-0553 | 1×10⁶ cells/vial: 500.00 EUR | |
Description: Homo sapiens, Human |
|
MDA-MB-175VII Cell Linefrom Elabscience Biotech |
|
CL-0381 | 1×10⁶ cells/vial: 500.00 EUR | |
Description: Homo sapiens, Human |
|
Human MDA-MB-361 Cell Lysatefrom Innovative research |
|
IHUMDAMB361TL100UG | each: 245.00 EUR | |
Description: Human MDA-MB-361 Cell Lysate |
|
OCPB00165-100UG - MDA-MB-361 Lysatefrom Aviva Systems Biology |
|
OCPB00165-100UG | 0.1mg: 139.00 EUR | |
CRISPRa (SAM) MDA-MB-231 Cell Linefrom BPS Bioscience |
|
78521 | 2 vials: 2500.00 EUR | |
Description: This cell line has been engineered for use with the CRISPR Synergistic Activation Mediator (SAM) system to induce transcriptional activation and expression of any gene of interest. Cells stably express a mutated dCas9 (Streptococcus pyogenes CRISPR-associated protein 9), lacking any endonuclease activity, fused to VP64, a transcriptional activator. Stable dCas9-VP64 expression is maintained with Blasticidin resistance. Cells also stably express a construct consisting of P65 (Transcription Factor p65, or Nuclear Factor NF-κB p65) and HSF1 (Heat Shock Factor 1) fused with an MS2 tag (from the MS2 coat protein), which is maintained with Hygromycin resistance. When these cells are transfected with an MS2 aptamer fused to a single guide RNA (sgRNA)targeting the promoter region of the gene of interest, dCas9-VP64 and MS2-P65-HSF1 are recruited to the promoter in the genomic DNA by the MS2 aptamer and begin transcription, inducing high level expression of the desired protein._x000D_Cells were functionally validated by transfecting the cells with an sgRNA-MS2 targeting PD-1, resulting in high expression of PD-1. |
|
MDA-MB-231 / TetR (Puro) stable cellsfrom GenTarget |
|
SC040-TetR | 2 x 106 cell/ml x 1ml: 1452.00 EUR | |
Description: Tetracycline repressor expression stable cell line with Puromycin marker in MDA-MB-231 human breast cancer cells. |
|
Human MDA-MB-435S Whole Cell Lysatefrom Innovative research |
|
IHUMDAMB435STLW500UG | each: 327.00 EUR | |
Description: Human MDA-MB-435S Whole Cell Lysate |
|
Cas9-Expressing MDA-MB-231 cell poolfrom BPS Bioscience |
|
78069 | 2 million cells: 795.00 EUR | |
Description: Cas9 (Streptococcus pyogenes CRISPR associated protein 9) is an endonuclease enzyme that, when recruited to a specific DNA sequence by the sgRNA (single guide RNA), introduces a double stranded break into the DNA. This double stranded break is repaired in mammalian cells either through Non-Homologous End Joining or Homologous Recombination. Non-Homologous End Joining often results in the deletion or insertion of several base pairs at the cut site, which, when resulting in a frameshift, causes the functional inactivation of the targeted gene. Cas9-expressing MDA-MB-231 cells can be transduced or electroporated with sgRNA targeting a gene of interest to quickly generate knock-out cell pools or cell lines. |
|
Human MDA-MB-435S Cell Lysate Lyophilizedfrom Innovative research |
|
IHUMDAMB435STLLY200UG | each: 89.00 EUR | |
Description: Human MDA-MB-435S Cell Lysate Lyophilized |
|
Human MDA-MB-361 (Breast Adenocarcinoma) lysatefrom Alpha Diagnostics |
|
HCL-1217 | 100ug: 285.60 EUR | |
MDA-MB-231 / GFP (Bsd) Stable Cell Linefrom GenTarget |
|
SC040-Bsd | 2 x 106 cell/ml x 1ml: 1452.00 EUR | |
Description: GFP expression stable cell line in MDA-MB-231 cells with Blasticidin resistance |
|
MDA-MB-231 / RFP (Bsd) Stable Cell Linefrom GenTarget |
|
SC057-Bsd | 2 x 106 cell/ml x 1ml: 1452.00 EUR | |
Description: RFP expression stable cell line in MDA-MB-231 cells with Blasticidin resistance |
|
MDA-MB-231 / GFP (Puro) Stable Cell Linefrom GenTarget |
|
SC040-Puro | 2 x 106 cell/ml x 1ml: 1452.00 EUR | |
Description: GFP expression stable cell line in MDA-MB-231 cells with Puromycin resistance |
|
MDA-MB-231 / Luciferase (Bsd) Stable Cell Linefrom GenTarget |
|
SC059-Bsd | 2 x 106 cell/ml x 1ml: 1800.00 EUR | |
Description: Luciferase (firefly) expression stable cell line in MDA-MB-231 cells with Blasticidin resistance |
|
GFP-Human MDA-MB-231 Breast Cancer Cellsfrom AcceGen |
|
ABC-RC207D | 1 vial: Ask for price | |
Description: Human MDA-MB-231 is a human adenocarcinoma cells derived from 51 year old (Caucasian) patient metastatic site. MDA-MB-231 are adherent epithelial like cells when culture with DMEM full medium containing 10% FBS. GFP-MDA-MB-231 cells are selected from puromycin resistant MDA-MB-231 after infected with GFP Expressing lentiviral particles. The cells are shipped in proliferating culture with >90 confluence or in a frozen vial with > 1.0 x 106cells/vial. |
|
RFP-Human MDA-MB-231 Breast Cancer Cellsfrom AcceGen |
|
ABC-RC208D | 1 vial: Ask for price | |
Description: Human MDA-MB-231 is a human adenocarcinoma cells derived from 51 year old (Caucasian) patient metastatic site. MDA-MB-231 are adherent epithelial like cells when culture with DMEM full medium containing 10% FBS. RFP-MDA-MB-231 cells are selected from Zeocin resistant MDA-MB-231 cells after infected with RFP expressing lentiviral particles. The cells are shipped in proliferating culture with >90 confluence or in a frozen vial with > 1.0 x 106cells/vial. |
|
MDA-MB-231 / Luciferase (Puro) Stable Cell Linefrom GenTarget |
|
SC059-Puro | 2 x 106 cell/ml x 1ml: 1800.00 EUR | |
Description: Luciferase (firefly) expression stable cell line in MDA-MB-231 cells with Puromycin resistance |
|
OCRA00105-500UG - MDA-MB-435S Whole Cell Lysatefrom Aviva Systems Biology |
|
OCRA00105-500UG | 500ug: 189.00 EUR | |
MDA-MB-231 / Luciferase-2A-RFP Stable Cell Linefrom GenTarget |
|
SC041 | 2 x 106 cell/ml x 1ml: 2670.00 EUR | |
Description: Firefly luciferase and GFP co-expression stable cell line in MDA-MB-231 cells with Blasticidin resistance |
|
MDA-MB-231 / Luciferase-2A-GFP Stable Cell Linefrom GenTarget |
|
SC044 | 2 x 106 cell/ml x 1ml: 2670.00 EUR | |
Description: Luciferase (firefry) and GFP co-expression stable cell line in MDA-MB-231 human breast cancer cell line with Puromycin marker. |
|
Human NFkB Luciferase Reporter Cell Line- MDA-MB-231from AcceGen |
|
ABC-RC0026 | 1 vial: Ask for price | |
Description: Human NFkB Luciferase Reporter Cell Line- MDA-MB-231 is derived from Human breast cancer, and stably express firefly luciferase reporter gene under the control of NFkB response element. This cell line is an ideal cellular model for monitoring the activation of NFkB response Pathway triggered by stimuli treatment, enforced gene expression and gene knockdown. |
|
MDA 19from MedChemExpress |
|
HY-15451 | 5mg: 151.20 EUR | |
MDA-kb2from AcceGen |
|
ABC-TC0647 | 1 vial: Ask for price | |
Description: Since both glucocorticoid receptor and androgen receptor are present in the MDA-MB-453 cells, and both receptors can act through the MMTV promoter, compounds that act through either androgen receptor or glucocorticoid receptor activate the MMTV luciferase. |
|
Cas9-Expressing MDA-MB-231 Cell Line (High or Low Expression)-78150-Hfrom BPS Bioscience |
|
78150-H | 2 vials: 6500.00 EUR | |
Description: This cell line is a clonal derivative from the Cas9-Expressing MDA-MB-231 Cell Pool (BPS Bioscience, #78069). It was generated by limited limiting dilution of the original pool and isolation of individual clones, which were screened based on Cas9 expression to obtain a low- or high-expressing cell line. The expressed Cas9 protein includes a C-terminal FLAG tag. |
|
Cas9-Expressing MDA-MB-231 Cell Line (High or Low Expression)-78150-Lfrom BPS Bioscience |
|
78150-L | 2 vials: 6500.00 EUR | |
Description: This cell line is a clonal derivative from the Cas9-Expressing MDA-MB-231 Cell Pool (BPS Bioscience, #78069). It was generated by limited limiting dilution of the original pool and isolation of individual clones, which were screened based on Cas9 expression to obtain a low- or high-expressing cell line. The expressed Cas9 protein includes a C-terminal FLAG tag. |
|
MDA-5 Antibodyfrom NSJ Bioreagents |
|
R35986-100UG | 100 ug: 339.15 EUR | |
Description: Additional name(s) for this target protein: Melanoma differentiation associated protein-5, IFIH1, interferon induced with helicase C domain 1 |
|
MDA Assay Kitfrom Fitzgerald |
|
55R-1512 | 100 assays: 970.80 EUR | |
Description: Assay Kit for detection of MDA in the research laboratory |
|
Human MDA ELISAfrom Kamiya Biomedical Company |
|
KT-53246 | 96 tests: 1013.00 EUR | |
MDA Adduct ELISAfrom Kamiya Biomedical Company |
|
KT-956 | 96 tests: 864.00 EUR | |
MDA-BSA Controlfrom Cell Biolabs |
|
STA-333 | 100 µg: 386.40 EUR | |
Description:
|
|
Malondialdehyde (MDA) (HSA)from Abbexa |
|
20-abx281005 | [ 100 ug: 693.60 EUR ] [ 10 ug: 309.60 EUR ] [ 1 mg: 2064.00 EUR ] [ 200 ug: 828.00 EUR ] [ 50 ug: 510.00 EUR ] | |
Malondialdehyde (MDA) ELISAfrom Kamiya Biomedical Company |
|
KT-21493 | 96 tests: 1032.00 EUR | |
MDA-7 Rabbit pAbfrom EnoGene |
|
E2251680 | 100ul: 225.00 EUR | |
Description: Available in various conjugation types. |
|
Malondialdehyde (MDA) Antibodyfrom Abbexa |
|
abx023266-1ml | 1 ml: 678.00 EUR | |
Malondialdehyde (MDA) Antibodyfrom Abbexa |
|
20-abx130475 | [ 100 ug: 477.60 EUR ] [ 10 ug: 159.60 EUR ] [ 1 mg: 1296.00 EUR ] [ 200 ug: 644.40 EUR ] [ 50 ug: 360.00 EUR ] | |
CD14(MDA/929) Antibodyfrom Biotium |
|
BNC800929-100 | 100uL: 238.80 EUR | |
Description: Primary antibody against CD14(MDA/929), CF680 conjugate, Concentration: 0.1mg/mL |
|
CD14(MDA/929) Antibodyfrom Biotium |
|
BNC800929-500 | 500uL: 652.80 EUR | |
Description: Primary antibody against CD14(MDA/929), CF680 conjugate, Concentration: 0.1mg/mL |
|
CD14(MDA/929) Antibodyfrom Biotium |
|
BNC810929-100 | 100uL: 238.80 EUR | |
Description: Primary antibody against CD14(MDA/929), CF680R conjugate, Concentration: 0.1mg/mL |
|
CD14(MDA/929) Antibodyfrom Biotium |
|
BNC810929-500 | 500uL: 652.80 EUR | |
Description: Primary antibody against CD14(MDA/929), CF680R conjugate, Concentration: 0.1mg/mL |
|
CD14(MDA/929) Antibodyfrom Biotium |
|
BNC940929-100 | 100uL: 238.80 EUR | |
Description: Primary antibody against CD14(MDA/929), CF594 conjugate, Concentration: 0.1mg/mL |
|
CD14(MDA/929) Antibodyfrom Biotium |
|
BNC940929-500 | 500uL: 652.80 EUR | |
Description: Primary antibody against CD14(MDA/929), CF594 conjugate, Concentration: 0.1mg/mL |
|
CD14(MDA/929) Antibodyfrom Biotium |
|
BNC700929-100 | 100uL: 238.80 EUR | |
Description: Primary antibody against CD14(MDA/929), CF770 conjugate, Concentration: 0.1mg/mL |
|
CD14(MDA/929) Antibodyfrom Biotium |
|
BNC700929-500 | 500uL: 652.80 EUR | |
Description: Primary antibody against CD14(MDA/929), CF770 conjugate, Concentration: 0.1mg/mL |
|
CD14(MDA/929) Antibodyfrom Biotium |
|
BNC880929-100 | 100uL: 238.80 EUR | |
Description: Primary antibody against CD14(MDA/929), CF488A conjugate, Concentration: 0.1mg/mL |
|
CD14(MDA/929) Antibodyfrom Biotium |
|
BNC880929-500 | 500uL: 652.80 EUR | |
Description: Primary antibody against CD14(MDA/929), CF488A conjugate, Concentration: 0.1mg/mL |
|
CD14(MDA/929) Antibodyfrom Biotium |
|
BNC050929-100 | 100uL: 238.80 EUR | |
Description: Primary antibody against CD14(MDA/929), CF405M conjugate, Concentration: 0.1mg/mL |
|
CD14(MDA/929) Antibodyfrom Biotium |
|
BNC050929-500 | 500uL: 652.80 EUR | |
Description: Primary antibody against CD14(MDA/929), CF405M conjugate, Concentration: 0.1mg/mL |
|
CD14(MDA/929) Antibodyfrom Biotium |
|
BNC040929-100 | 100uL: 238.80 EUR | |
Description: Primary antibody against CD14(MDA/929), CF405S conjugate, Concentration: 0.1mg/mL |
|
CD14(MDA/929) Antibodyfrom Biotium |
|
BNC040929-500 | 500uL: 652.80 EUR | |
Description: Primary antibody against CD14(MDA/929), CF405S conjugate, Concentration: 0.1mg/mL |
|
CD14(MDA/929) Antibodyfrom Biotium |
|
BNC400929-100 | 100uL: 238.80 EUR | |
Description: Primary antibody against CD14(MDA/929), CF640R conjugate, Concentration: 0.1mg/mL |
|
CD14(MDA/929) Antibodyfrom Biotium |
|
BNC400929-500 | 500uL: 652.80 EUR | |
Description: Primary antibody against CD14(MDA/929), CF640R conjugate, Concentration: 0.1mg/mL |
|
CD14(MDA/929) Antibodyfrom Biotium |
|
BNCB0929-100 | 100uL: 238.80 EUR | |
Description: Primary antibody against CD14(MDA/929), Biotin conjugate, Concentration: 0.1mg/mL |
|
CD14(MDA/929) Antibodyfrom Biotium |
|
BNCB0929-500 | 500uL: 652.80 EUR | |
Description: Primary antibody against CD14(MDA/929), Biotin conjugate, Concentration: 0.1mg/mL |
|
CD14(MDA/929) Antibodyfrom Biotium |
|
BNCAP0929-100 | 100uL: 238.80 EUR | |
Description: Primary antibody against CD14(MDA/929), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|
CD14(MDA/929) Antibodyfrom Biotium |
|
BNCAP0929-500 | 500uL: 652.80 EUR | |
Description: Primary antibody against CD14(MDA/929), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|
CD14(MDA/929) Antibodyfrom Biotium |
|
BNCA0929-250 | 250uL: 459.60 EUR | |
Description: Primary antibody against CD14(MDA/929), APC conjugate, Concentration: 0.1mg/mL |
|
CD14(MDA/929) Antibodyfrom Biotium |
|
BNCR0929-250 | 250uL: 459.60 EUR | |
Description: Primary antibody against CD14(MDA/929), RPE conjugate, Concentration: 0.1mg/mL |
|
CD14(MDA/929) Antibodyfrom Biotium |
|
BNCP0929-250 | 250uL: 459.60 EUR | |
Description: Primary antibody against CD14(MDA/929), PerCP conjugate, Concentration: 0.1mg/mL |
|
CD14(MDA/929) Antibodyfrom Biotium |
|
BNUM0929-50 | 50uL: 474.00 EUR | |
Description: Primary antibody against CD14(MDA/929), 1mg/mL |
|
CD14(MDA/929) Antibodyfrom Biotium |
|
BNCH0929-100 | 100uL: 238.80 EUR | |
Description: Primary antibody against CD14(MDA/929), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|
CD14(MDA/929) Antibodyfrom Biotium |
|
BNCH0929-500 | 500uL: 652.80 EUR | |
Description: Primary antibody against CD14(MDA/929), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|
CD14(MDA/929) Antibodyfrom Biotium |
|
BNUB0929-100 | 100uL: 250.80 EUR | |
Description: Primary antibody against CD14(MDA/929), Concentration: 0.2mg/mL |
|
CD14(MDA/929) Antibodyfrom Biotium |
|
BNUB0929-500 | 500uL: 549.60 EUR | |
Description: Primary antibody against CD14(MDA/929), Concentration: 0.2mg/mL |
|
CD14(MDA/929) Antibodyfrom Biotium |
|
BNC610929-100 | 100uL: 238.80 EUR | |
Description: Primary antibody against CD14(MDA/929), CF660R conjugate, Concentration: 0.1mg/mL |
|
CD14(MDA/929) Antibodyfrom Biotium |
|
BNC610929-500 | 500uL: 652.80 EUR | |
Description: Primary antibody against CD14(MDA/929), CF660R conjugate, Concentration: 0.1mg/mL |
|
CD14(MDA/929) Antibodyfrom Biotium |
|
BNC550929-100 | 100uL: 238.80 EUR | |
Description: Primary antibody against CD14(MDA/929), CF555 conjugate, Concentration: 0.1mg/mL |